Institution
Shanghai Jiao Tong University
Education•Shanghai, Shanghai, China•
About: Shanghai Jiao Tong University is a education organization based out in Shanghai, Shanghai, China. It is known for research contribution in the topics: Population & Cancer. The organization has 157524 authors who have published 184620 publications receiving 3451038 citations. The organization is also known as: Shanghai Communications University & Shanghai Jiaotong University.
Topics: Population, Cancer, Microstructure, Cell growth, Metastasis
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Shanghai 200031, China; Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Chinese academy of sciences, Shanghai200032, China.
Abstract: Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Shanghai 200031, China; Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Chinese Academy of Sciences, Shanghai 200032, China; Key Laboratory of Systems Biomedicine, Ministry of Education, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China; National Engineering Research Center for the Emergence Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China; The Joint Program in Infection and Immunity: a. Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, China; b. Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China
1,735 citations
••
University of Sydney1, University Hospitals Birmingham NHS Foundation Trust2, Newcastle upon Tyne Hospitals NHS Foundation Trust3, Spanish National Research Council4, University of Haifa5, The Chinese University of Hong Kong6, University of Bern7, University of Mainz8, Kurume University9, Pontifical Catholic University of Chile10, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico11, Mansoura University12, Minerva Foundation Institute for Medical Research13, Shanghai Jiao Tong University14, Aarhus University Hospital15, Marmara University16, University of Lisbon17, University of São Paulo18, Paris Diderot University19, University of Western Australia20, First Affiliated Hospital of Wenzhou Medical University21, Minia University22, University of Malaya23, National Autonomous University of Mexico24, Yonsei University25, University of Paris26, University of Turin27
TL;DR: A panel of international experts from 22 countries propose a new definition of metabolic-dysfunction-associated fatty liver disease that is both comprehensive yet simple for the diagnosis of MAFLD and is independent of other liver diseases.
1,705 citations
••
TL;DR: Afatinib significantly improves progression-free survival with a tolerable and manageable safety profile in Asian patients with EGFR mutation-positive advanced lung NSCLC and should be considered as a first-line treatment option for this patient population.
Abstract: Summary Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). We compared afatinib with gemcitabine and cisplatin—a chemotherapy regimen widely used in Asia—for first-line treatment of Asian patients with EGFR mutation-positive advanced NSCLC. Methods This open-label, randomised phase 3 trial was done at 36 centres in China, Thailand, and South Korea. After central testing for EGFR mutations, treatment-naive patients (stage IIIB or IV cancer [American Joint Committee on Cancer version 6], performance status 0–1) were randomly assigned (2:1) to receive either oral afatinib (40 mg per day) or intravenous gemcitabine 1000 mg/m 2 on day 1 and day 8 plus cisplatin 75 mg/m 2 on day 1 of a 3-week schedule for up to six cycles. Randomisation was done centrally with a random number-generating system and an interactive internet and voice-response system. Randomisation was stratified by EGFR mutation (Leu858Arg, exon 19 deletions, or other; block size three). Clinicians and patients were not masked to treatment assignment, but the independent central imaging review group were. Treatment continued until disease progression, intolerable toxic effects, or withdrawal of consent. The primary endpoint was progression-free survival assessed by independent central review (intention-to-treat population). This study is registered with ClinicalTrials.gov, NCT01121393. Findings 910 patients were screened and 364 were randomly assigned (242 to afatinib, 122 to gemcitabine and cisplatin). Median progression-free survival was significantly longer in the afatinib group (11·0 months, 95% CI 9·7–13·7) than in the gemcitabine and cisplatin group (5·6 months, 5·1–6·7; hazard ratio 0·28, 95% CI 0·20–0·39; p Interpretation First-line afatinib significantly improves progression-free survival with a tolerable and manageable safety profile in Asian patients with EGFR mutation-positive advanced lung NSCLC. Afatinib should be considered as a first-line treatment option for this patient population. Funding Boehringer Ingelheim.
1,695 citations
••
TL;DR: The results reveal a spin-momentum locked Dirac cone carrying a non-trivial Berry’s phase that is nearly 100 per cent spin-polarized, which exhibits a tunable topological fermion density in the vicinity of the Kramers point and can be driven to the long-sought topological spin transport regime.
Abstract: Helical Dirac fermions—charge carriers that behave as massless relativistic particles with an intrinsic angular momentum (spin) locked to its translational momentum—are proposed to be the key to realizing fundamentally new phenomena in condensed matter physics. Prominent examples include the anomalous quantization of magneto-electric coupling, half-fermion states that are their own antiparticle, and charge fractionalization in a Bose– Einstein condensate, all of which are not possible with conventional Dirac fermions of the graphene variety. Helical Dirac fermions have so far remained elusive owing to the lack of necessary spin-sensitive measurements and because such fermions are forbidden to exist in conventional materials harbouring relativistic electrons, such as graphene or bismuth. It has recently
been proposed that helical Dirac fermions may exist at the edges of certain types of topologically ordered insulators—materials with a bulk insulating gap of spin–orbit origin and surface states protected against scattering by time-reversal symmetry—and that their peculiar properties may be accessed provided the insulator is tuned into the so-called topological transport regime. However, helical Dirac fermions have not been observed in existing topological insulators. Here we report the realization and characterization of a tunable topological insulator in a bismuthbased class of material by combining spin-imaging and
momentum-resolved spectroscopies, bulk charge compensation,
Hall transport measurements and surface quantum control. Our
results reveal a spin-momentum locked Dirac cone carrying a nontrivial
Berry’s phase that is nearly 100 per cent spin-polarized,
which exhibits a tunable topological fermion density in the vicinity
of the Kramers point and can be driven to the long-sought
topological spin transport regime. The observed topological nodal
state is shown to be protected even up to 300 K. Our demonstration
of room-temperature topological order and non-trivial spintexture
in stoichiometric Bi_2Se_3.M_x (M_x indicates surface doping
or gating control) paves the way for future graphene-like studies of
topological insulators, and applications of the observed spinpolarized
edge channels in spintronic and computing technologies
possibly at room temperature.
1,685 citations
••
TL;DR: A meta-analysis of randomised controlled trials to compare the effects of second-generation antipsychotic drugs in patients with schizophrenia provided data for individualised treatment based on efficacy, side-effects, and cost.
1,682 citations
Authors
Showing all 158621 results
Name | H-index | Papers | Citations |
---|---|---|---|
Meir J. Stampfer | 277 | 1414 | 283776 |
Richard A. Flavell | 231 | 1328 | 205119 |
Jie Zhang | 178 | 4857 | 221720 |
Yang Yang | 171 | 2644 | 153049 |
Lei Jiang | 170 | 2244 | 135205 |
Gang Chen | 167 | 3372 | 149819 |
Thomas S. Huang | 146 | 1299 | 101564 |
Barbara J. Sahakian | 145 | 612 | 69190 |
Jean-Laurent Casanova | 144 | 842 | 76173 |
Kuo-Chen Chou | 143 | 487 | 57711 |
Weihong Tan | 140 | 892 | 67151 |
Xin Wu | 139 | 1865 | 109083 |
David Y. Graham | 138 | 1047 | 80886 |
Bin Liu | 138 | 2181 | 87085 |
Jun Chen | 136 | 1856 | 77368 |